Assistance Publique - Hôpitaux de Paris: Sclerosis trials

The registry lists 31 Sclerosis studies with Assistance Publique - Hôpitaux de Paris as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 5Phase 3 5No phase 21(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I/II Randomized Clinical Trial of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells Systemic Infusion in Severe Systemic SclerosisNot yet recruitingNCT06722105Phase 1/2
• Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple SclerosisNot yet recruitingNCT06330077Phase 2
• Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell TransplantationNot yet recruitingNCT05960058
• Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic SclerosisNot yet recruitingNCT05947682Not applicable
• Effect of Salbutamol on Walking Capacity in Ambulatory ALS PatientsNot yet recruitingNCT05860244Phase 2
• Stratification of Presymptomatic Amyotrophic Lateral Sclerosis: the Development of Novel Imaging BiomarkersRecruitingNCT05358431Not applicable
• Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of NeuroinflammationRecruitingNCT05147532Not applicable
• Cell Signaling, Reinnervation and Metabolism in Kennedy Disease and Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT05107349Not applicable
• Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714RecruitingNCT03691077Phase 3
• Quality of Life Evaluation with the SRI Questionnaire of ALS Patient with Non-invasive VentilationCompletedNCT05498883Not applicable
• Study of Empathy in MSCompletedNCT05332951
• Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple SclerosisCompletedNCT05033782
• Study of the Intestinal Microbiota of Patients With Systemic SclerosisStatus unknownNCT04791280
• Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity DeficitStatus unknownNCT04563832Not applicable
• Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic SclerosisCompletedNCT03717961Phase 3
• Presymptomatic Neuromuscular Junction Defects and Compensatory Mechanisms in ALSStatus unknownNCT03573466Not applicable
• Acoustic and Perceptual Markers of Dysarthria in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT03560661
• Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)Status unknownNCT03154801Not applicable
• Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02590276Not applicable
• Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple SclerosisCompletedNCT02424396Phase 2
• Physical Capacity and Rehabilitation of Patients With Multiple SclerosisStatus unknownNCT02352194
• Imaging of Intracerebral Inflammation in MSCompletedNCT02305264Not applicable
• A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis PatientsCompletedNCT01871818Not applicable
• Prognosis Value of the Neuronal Damage in Early Multiple SclerosisStatus unknownNCT01651520Not applicable
• Early Stage Amyotrophic Lateral Sclerosis Phrenic StimulationTerminatedNCT01583088Phase 3
• Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and ControlsCompletedNCT01160263Phase 3
• Early Cognitive Impairment in Multiple SclerosisCompletedNCT01157728
• Effect of Lithium Carbonate in Patients With Amyotrophic Lateral SclerosisCompletedNCT00925847Phase 2
• Neuromuscular Transmission in Amyotrophic Lateral SclerosisCompletedNCT00847847Not applicable
• Efficacy of 3,4-DAP in Fatigue Associated With Multiple SclerosisCompletedNCT00190268Phase 3
• Amyotrophic Lateral Sclerosis and Frontotemporal DementiaTerminatedNCT00159198